Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
7,848
Views
83
CrossRef citations to date
0
Altmetric
Review

Trial watch: IDO inhibitors in cancer therapy

Julie Le Naoura Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France;c Gustave Roussy Cancer Campus, Villejuif, France;d Faculty of Medicine Kremlin Bicêtre, Université Paris Sud, Paris Saclay, FranceORCID Iconhttps://orcid.org/0000-0002-3749-2171
ORCID Icon,
Lorenzo Galluzzie Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA;f Sandra and Edward Meyer Cancer Center, New York, NY, USA;g Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA;h Department of Dermatology, Yale School of Medicine, New Haven, CT, USA;i Université De Paris, Paris, FranceORCID Iconhttps://orcid.org/0000-0003-2257-8500
ORCID Icon,
Laurence Zitvogelc Gustave Roussy Cancer Campus, Villejuif, France;j Equipe Labellisée Ligue Contre Le Cancer, Villejuif, France;k Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0003-1596-0998
ORCID Icon,
Guido Kroemera Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France;c Gustave Roussy Cancer Campus, Villejuif, France;k Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France;l Hôpital Européen Georges Pompidou, AP-HP, Paris, France;m Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China;n Karolinska Institute, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon &
Erika Vacchellia Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France;c Gustave Roussy Cancer Campus, Villejuif, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8010-0594
ORCID Icon
Article: 1777625 | Received 13 May 2020, Accepted 31 May 2020, Published online: 14 Jun 2020

Citations (83)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Fahimeh Heidari, Amin Ramezani, Nasrollah Erfani & Mahboobeh Razmkhah. (2022) Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases. International Reviews of Immunology 41:3, pages 346-363.
Read now
Sarah-Jane Leigh, Caoimhe M.K. Lynch, Brian R. Healey Bird, Brendan T. Griffin, John F. Cryan & Gerard Clarke. (2022) Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects. Expert Opinion on Drug Metabolism & Toxicology 18:1, pages 5-26.
Read now

Articles from other publishers (81)

Yubo Gong, Chenchen Zhang, Hao Li, Xiaojie Yu, Yuejia Li, Zhiguo Liu & Ruyi He. (2024) Ferroptosis-Related lncRNA to Predict the Clinical Outcomes and Molecular Characteristics of Kidney Renal Papillary Cell Carcinoma. Current Issues in Molecular Biology 46:3, pages 1886-1903.
Crossref
Er Jin, Zhidong Yin, Xiuxiu Zheng, Chenhong Yan, Kai Xu, Fouejio Yemele Eunice & Yue Gao. (2024) Potential of Targeting TDO2 as the Lung Adenocarcinoma Treatment. Journal of Proteome Research.
Crossref
Ondrej Uher, Katerina Hadrava Vanova, David Taïeb, Bruna Calsina, Mercedes Robledo, Roderick Clifton-Bligh & Karel Pacak. (2024) The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives. Endocrine Reviews.
Crossref
Patrizia Leone, Eleonora Malerba, Nicola Susca, Elvira Favoino, Federico Perosa, Giuliano Brunori, Marcella Prete & Vito Racanelli. (2024) Endothelial cells in tumor microenvironment: insights and perspectives. Frontiers in Immunology 15.
Crossref
Moksada Regmi, Yingjie Wang, Weihai Liu, Yuwei Dai, Shikun Liu, Ke Ma, Guozhong Lin, Jun Yang, Hongyi Liu, Jian Wu & Chenlong Yang. (2024) From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review. Journal of Experimental & Clinical Cancer Research 43:1.
Crossref
Jiawei Zhang, Jingyi Liu, Kaimin Kong, Xingzhou Li & Qian Zhang. (2024) Structure–activity relationship studies of 5-(Pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 inhibitors. Results in Chemistry 7, pages 101285.
Crossref
Nayeon Shim, Hanhee Cho, Seong Ik Jeon & Kwangmeyung Kim. (2023) Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy. Journal of Pharmaceutical Investigation 54:1, pages 13-36.
Crossref
Anuradha Mehra & Rekha Sangwan. (2023) Synthesis and Pharmacological Properties of the Benzimidazole Scaffold: A Patent Review. ChemistrySelect 8:45.
Crossref
Elnaz Jalilian, Firoozeh Abolhasani-Zadeh, Ali Afgar, Arash Samoudi, Hamid Zeinalynezhad & Ladan Langroudi. (2023) Neutralizing tumor-related inflammation and reprogramming of cancer-associated fibroblasts by Curcumin in breast cancer therapy. Scientific Reports 13:1.
Crossref
Kazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, Takuya Tsujino, Kazuki Nishimura, Mitsuaki Ishida, Takuo Hayashi, Ayako Ura, Takaya Ohno, Shogo Yamazaki, Keita Nakamori, Shoko Kinoshita, Ryoichi Maenosono, Masahiko Ajiro, Yuki Yoshikawa, Tomoaki Takai, Takeshi Tsutsumi, Kohei Taniguchi, Tomohito Tanaka, Kiyoshi Takahara, Tsuyoshi Konuma, Teruo Inamoto, Yoshinobu Hirose, Fumihito Ono, Yuichi Shiraishi, Akihide Yoshimi & Haruhito Azuma. (2023) The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer. Molecular Cancer 22:1.
Crossref
Zhiren Wang, Wenpan Li, Yanhao Jiang, Tuyen Ba Tran, Leyla Estrella Cordova, Jinha Chung, Minhyeok Kim, Georg Wondrak, Jennifer Erdrich & Jianqin Lu. (2023) Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy. Nature Communications 14:1.
Crossref
Shurong Zhou, Furong Cheng, Yu Zhang, Ting Su & Guizhi Zhu. (2023) Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases. Accounts of Chemical Research 56:21, pages 2933-2943.
Crossref
Xiaofeng Zou, Deming Zhao, Xin Wen & Feihong Chen. (2023) NLG-919 combined with cisplatin to enhance inhibitory effect on cell migration and invasion via IDO1–Kyn–AhR pathway in human nasopharyngeal carcinoma cell. Canadian Journal of Physiology and Pharmacology 101:11, pages 599-609.
Crossref
Donald F. Weaver. (2023) Druggable targets for the immunopathy of Alzheimer's disease. RSC Medicinal Chemistry 14:9, pages 1645-1661.
Crossref
M. Teresa Agulló-Ortuño, Esther Mancebo, Montserrat Grau, Juan Antonio Núñez Sobrino, Luis Paz-Ares, José A. López-Martín & Marta Flández. (2023) Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models. International Journal of Molecular Sciences 24:16, pages 13005.
Crossref
Ai Sumiyoshi, Hiroyuki Fujii & Yusuke Okuma. (2023) Targeting microbiome, drug metabolism, and drug delivery in oncology. Advanced Drug Delivery Reviews 199, pages 114902.
Crossref
Chaoyue Xiao, Wei Xiong, Yiting Xu, Ji’an Zou, Yue Zeng, Junqi Liu, Yurong Peng, Chunhong Hu & Fang Wu. (2023) Immunometabolism: a new dimension in immunotherapy resistance. Frontiers of Medicine 17:4, pages 585-616.
Crossref
Pengbo Yang & Junhua Zhang. (2023) Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy. Biomedicines 11:7, pages 1988.
Crossref
Xuanrun Hao, Zhongliang Chen, Haining Li, Minqin Wei, Zhili Zuo & Qing Su. (2023) Small-Molecule Drugs in Immunotherapy. Mini-Reviews in Medicinal Chemistry 23:13, pages 1341-1359.
Crossref
Qiuyu Zhuang, Binyu Zhao, Zhiwen Lin, Yuzhi Liang, Qingfu Zhao, Yunhao Wang, Naishun Liao, Haibin Tu, Youshi Zheng, Hengkai Chen, Yongyi Zeng, Da Zhang & Xiaolong Liu. (2023) Navoximod modulates local HSV-1 replication to reshape tumor immune microenvironment for enhanced immunotherapy via an injectable hydrogel. Communications Biology 6:1.
Crossref
Leila Moeinzadeh, Amin Ramezani, Fereshteh Mehdipour, Mahsa Yazdanpanah-Samani & Mahboobeh Razmkhah. (2023) Activation of T Lymphocytes with Anti-PDL1-BiTE in the Presence of Adipose-Derived Mesenchymal Stem Cells (ASCs). BioMed Research International 2023, pages 1-11.
Crossref
Wenshuai Li, Xuanxuan Pan, Lirong Chen, Haoshu Cui, Shaocong Mo, Yida Pan, Yuru Shen, Menglin Shi, Jianlin Wu, Feifei Luo, Jie Liu & Na Li. (2023) Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy. Frontiers in Immunology 14.
Crossref
Hada Buhe, Ji-xin Ma, Fang-zhou Ye, Chen-yun Song, Xin-yu Chen, Yang Liu, Huang Lin, Xu Han, Li-xiang Ma & Hexige Saiyin. (2022) IDO-1 inhibitor INCB24360 elicits distant metastasis of basal extruded cancer cells in pancreatic ductal adenocarcinoma. Acta Pharmacologica Sinica 44:6, pages 1277-1289.
Crossref
Karl Savonije, Autumn Meek & Donald F. Weaver. (2023) Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression. Brain Sciences 13:6, pages 852.
Crossref
Shonik Ganjoo, Priti Gupta, Halil Ibrahim Corbali, Selene Nanez, Thomas S. Riad, Lisa K. Duong, Hampartsoum B. Barsoumian, Fatemeh Masrorpour, Hong Jiang, James W. Welsh & Maria Angelica Cortez. (2023) The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy. Frontiers in Immunology 14.
Crossref
Jennifer Cao, Lyndah Chow & Steven Dow. (2023) Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment. Frontiers in Oncology 13.
Crossref
Katarzyna Starska-Kowarska. (2023) The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. Cancers 15:6, pages 1642.
Crossref
Zhe Yang, Di Gao, Jing Zhao, Gaojie Yang, Ming Guo, Ying Wang, Xuechun Ren, Jong Seung Kim, Lin Jin, Zhongmin Tian & Xingcai Zhang. (2023) Thermal immuno-nanomedicine in cancer. Nature Reviews Clinical Oncology 20:2, pages 116-134.
Crossref
Zipeng Zhang, Shuang Liang, Shunli Fu, Tong Gao, Weiwei Mu, Lili Chang, Shujun Liu, Yongjun Liu & Na Zhang. (2023) In-situ self-assembled vaccine constructed with dual switchable nanotransformer for tumor immunotherapy. Chemical Engineering Journal 454, pages 140190.
Crossref
Tianyang Wang & Yan-Mei Li. (2023) Progress on the Synthesis and Activity of Cyclic Dinucleotides as Stimulator of Interferon Gene (STING) Agonists. Chinese Journal of Organic Chemistry 43:3, pages 892.
Crossref
Veronika Voronova, Anastasia Vislobokova, Kerim Mutig, Mikhail Samsonov, Kirill Peskov, Marina Sekacheva, Maria Materenchuk, Natalya Bunyatyan & Svetlana Lebedeva. (2022) Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. Frontiers in Oncology 12.
Crossref
Philippa R. Kennedy, Martin Felices & Jeffrey S. Miller. (2022) Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer. Stem Cell Research & Therapy 13:1.
Crossref
Qingxin Fan, Jing Zuo, Hailong Tian, Canhua Huang, Edouard C. Nice, Zheng Shi & Qingquan Kong. (2022) Nanoengineering a metal–organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Yan Tie, Fan Tang, Yu-quan Wei & Xia-wei Wei. (2022) Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. Journal of Hematology & Oncology 15:1.
Crossref
Yang Yang, Xiaoli Zheng, Peizan Ni, Dingjie Li, Qinfu Dan, Xiaohui Wang, Yunhan Wang, Yanan Sun, Kangdong Liu, Zigang Dong & Hong Ge. (2022) Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC. International Journal of Oncology 62:1.
Crossref
Chenglong Liu, Mengxuan Yang, Daizhou Zhang, Ming Chen & Di Zhu. (2022) Clinical cancer immunotherapy: Current progress and prospects. Frontiers in Immunology 13.
Crossref
Enrica Marmonti, Jacqueline Oliva-Ramirez & Cara Haymaker. (2022) Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. Cells 11:19, pages 3028.
Crossref
Ginette S. Santiago-Sánchez, James W. Hodge & Kellsye P. Fabian. (2022) Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. Frontiers in Immunology 13.
Crossref
Anna Passarelli, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Sabrina Rossetti, Rosa Tambaro, Jole Ventriglia, Federica Gherardi, Eva Iannacone, Sergio Setola Venanzio, Francesco Fiore, Michele Bartoletti, Giosuè Scognamiglio, Daniela Califano & Sandro Pignata. (2022) Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer. Frontiers in Immunology 13.
Crossref
Xuanyu Zhu, Longfei Zhu & Yan Wu. (2022) Manipulating Metabolic Alterations and their Consequences to Unleash the Potential of Antitumor Immunotherapy. Current Protein & Peptide Science 23:9, pages 585-601.
Crossref
Kalliopi Domvri, Savvas Petanidis, Paul Zarogoulidis, Doxakis Anestakis, Charalampos Charalampidis, Drosos Tsavlis, Haidong Huang, Lutz Freitag, Wolfgang Hohenforst-Schmidt, Dimitris Matthaios, Theodora Katopodi & Konstantinos Porpodis. (2022) Engineered Hybrid Treg-Targeted Nanosomes Restrain Lung Immunosuppression by Inducing Intratumoral CD8+T Cell Immunity. International Journal of Nanomedicine Volume 17, pages 4449-4468.
Crossref
Yuhao Yang, Jingyi Zeng & Ruijia Zhao. (2022) Emerging Vaccine Immunotherapy In NSCLC: The Adverse Reactions of Recent Clinical Trials and Future Directions. Highlights in Science, Engineering and Technology 8, pages 94-99.
Crossref
Marta Sowińska, Monika Szeliga, Maja Morawiak, Barbara Zabłocka & Zofia Urbanczyk-Lipkowska. (2022) Design, Synthesis and Activity of New N1-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma. Biomolecules 12:8, pages 1116.
Crossref
Santiago Moragon, Cristina Hernando, Maria Teresa Martinez-Martinez, Marta Tapia, Belen Ortega-Morillo, Ana Lluch, Begoña Bermejo & Juan Miguel Cejalvo. (2022) Immunological Landscape of HER-2 Positive Breast Cancer. Cancers 14:13, pages 3167.
Crossref
Peiru Chen, Dali Wang, Yuyan Wang, Lei Zhang, Qiwei Wang, Lanxia Liu, Jiahe Li, Xin Sun, Mengqi Ren, Ruoxuan Wang, Yang Fang, Jean J. Zhao & Ke Zhang. (2022) Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids. Nano Letters 22:10, pages 4058-4066.
Crossref
Nina Schoenwaelder, Mareike Krause, Thomas Freitag, Björn Schneider, Sarah Zonnur, Annette Zimpfer, Anne Sophie Becker, Inken Salewski, Daniel Fabian Strüder, Heiko Lemcke, Christina Grosse-Thie, Christian Junghanss & Claudia Maletzki. (2022) Preclinical Head and Neck Squamous Cell Carcinoma Models for Combined Targeted Therapy Approaches. Cancers 14:10, pages 2484.
Crossref
Andrea Mammoli, Elisa Bianconi, Luana Ruta, Alessandra Riccio, Carlo Bigiotti, Maria Souma, Andrea Carotti, Sofia Rossini, Chiara Suvieri, Maria Teresa Pallotta, Ursula Grohmann, Emidio Camaioni & Antonio Macchiarulo. (2022) Critical Assessment of a Structure-Based Screening Campaign for IDO1 Inhibitors: Tips and Pitfalls. International Journal of Molecular Sciences 23:7, pages 3981.
Crossref
Xujun Cao, Anthony F. Cordova & Lingyin Li. (2021) Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act. Chemical Reviews 122:3, pages 3414-3458.
Crossref
Yan Li, Chen Yang, Zhicheng Liu, Shangce Du, Susan Can, Hailin Zhang, Linmeng Zhang, Xiaowen Huang, Zhenyu Xiao, Xiaobo Li, Jingyuan Fang, Wenxin Qin, Chong Sun, Cun Wang, Jun Chen & Huimin Chen. (2022) Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy. Molecular Cancer 21:1.
Crossref
Saeko Yoshioka, Tomonori Ikeda, Sogo Fukuchi, Yurika Kawai, Katsumi Ohta, Hisashi Murakami, Naohisa Ogo, Daisuke Muraoka, Osamu Takikawa & Akira Asai. (2022) Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase. International Journal of Tryptophan Research 15, pages 117864692211384.
Crossref
Sarah Tettamanti, Alice Pievani, Andrea Biondi, Gianpietro Dotti & Marta Serafini. (2021) Catch me if you can: how AML and its niche escape immunotherapy. Leukemia 36:1, pages 13-22.
Crossref
Susann Schönefeldt, Tamara Wais, Marco Herling, Satu Mustjoki, Vasileios Bekiaris, Richard Moriggl & Heidi A. Neubauer. (2021) The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma. Cancers 13:24, pages 6212.
Crossref
Fan Li, Zhenyu Zhao, Zongbiao Zhang, Yan Zhang & Wei Guan. (2021) Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner. BMC Cancer 21:1.
Crossref
Chenfeng Han, Minmin Ge, Ping-Chih Ho & Lianjun Zhang. (2021) Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited. Cancer Immunology Research 9:12, pages 1373-1382.
Crossref
G. Antonarelli, C. Corti, P. Tarantino, L. Ascione, J. Cortes, P. Romero, E.A. Mittendorf, M.L. Disis & G. Curigliano. (2021) Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Annals of Oncology 32:12, pages 1537-1551.
Crossref
Fahimeh Heidari, Mahboobeh Razmkhah, Vahid Razban & Nasrollah Erfani. (2021) Effects of indoleamine 2, 3‐dioxygenase (IDO) silencing on immunomodulatory function and cancer‐promoting characteristic of adipose‐derived mesenchymal stem cells (ASCs). Cell Biology International 45:12, pages 2544-2556.
Crossref
Silvia Fallarini, Irene P. Bhela, Silvio Aprile, Enza Torre, Alice Ranza, Elena Orecchini, Eleonora Panfili, Maria T. Pallotta, Alberto Massarotti, Marta Serafini & Tracey Pirali. (2021) The [1,2,4]Triazolo[4,3‐ a ]pyridine as a New Player in the Field of IDO1 Catalytic Holo‐Inhibitors . ChemMedChem 16:22, pages 3439-3450.
Crossref
Lingyan Xu, Jiawei Ling, Chang Su, Yu-Wen Su, Yan Xu & Zhenzhou Jiang. (2021) Emerging Roles on Immunological Effect of Indoleamine 2,3-Dioxygenase in Liver Injuries. Frontiers in Medicine 8.
Crossref
Chih-Ta Chen, Pei-Hua Wu, Chia-Chi Hu, Hsiao-Ching Nien, Jin-Town Wang, Jin-Chuan Sheu & Lu-Ping Chow. (2021) Aberrant Upregulation of Indoleamine 2,3-Dioxygenase 1 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Cells via Coordinated Activation of AhR and β-Catenin Signaling. International Journal of Molecular Sciences 22:21, pages 11661.
Crossref
Nan Wang, Rongshui Wang, Xia Li, Zhentao Song, Lingbo Xia, Jue Wang, Li Zhang, Aiwen Wu & Zhiyong Ding. (2021) Tumor Microenvironment Profiles Reveal Distinct Therapy-Oriented Proteogenomic Characteristics in Colorectal Cancer. Frontiers in Bioengineering and Biotechnology 9.
Crossref
Kai Li, Houhui Shi, Benxia Zhang, Xuejin Ou, Qizhi Ma, Yue Chen, Pei Shu, Dan Li & Yongsheng Wang. (2021) Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduction and Targeted Therapy 6:1.
Crossref
Xianyan Qin, Liming He, Chenglan Feng, Donghao Fan, Wenlang Liang, Qin Wang & Jiyu Fang. (2021) Injectable Micelle-Incorporated Hydrogels for the Localized Chemo-Immunotherapy of Breast Tumors. ACS Applied Materials & Interfaces 13:39, pages 46270-46281.
Crossref
Zilai Wang, Norton P. Peet, Pin Zhang, Yuwei Jiang & Lijun Rong. (2021) Current Development of Glioblastoma Therapeutic Agents. Molecular Cancer Therapeutics 20:9, pages 1521-1532.
Crossref
Yajing Du, Sujuan Yuan, Xibing Zhuang, Qi Zhang & Tiankui Qiao. (2021) Multiomics Differences in Lung Squamous Cell Carcinoma Patients with High Radiosensitivity Index Compared with Those with Low Radiosensitivity Index. Disease Markers 2021, pages 1-11.
Crossref
Chu-Ling Li & Yong Song. (2021) Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges. Chinese Medical Journal 134:16, pages 1908-1919.
Crossref
Farhan Z. Ilyas, Joal D. Beane & Timothy M. Pawlik. (2021) The State of Immunotherapy in Hepatobiliary Cancers. Cells 10:8, pages 2096.
Crossref
Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni, Lidia Gatto, Raffaele Lodi, Stefania Bartolini & Alba Ariela Brandes. (2021) Glioblastoma: Emerging Treatments and Novel Trial Designs. Cancers 13:15, pages 3750.
Crossref
Aalok Patwa, Rikiya Yamashita, Jin Long, Tyler Risom, Michael Angelo, Leeat Keren & Daniel L. Rubin. (2021) Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer. Communications Biology 4:1.
Crossref
Xiaochen Yang, Wing Lam, Zaoli Jiang, Fulan Guan, Xue Han, Rong Hu, Wei Cai, William Cheng, Shwu-Huey Liu, Peikwen Cheng, Yuping Cai, Nicholas J. W. Rattray, Caroline H. Johnson, Lieping Chen & Yung-Chi Cheng. (2021) YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports 11:1.
Crossref
Adrian Mor, Anna Tankiewicz-Kwedlo & Dariusz Pawlak. (2021) Kynurenines as a Novel Target for the Treatment of Malignancies. Pharmaceuticals 14:7, pages 606.
Crossref
Kristen B. McCullough, Alexis K. Kuhn & Mrinal M. Patnaik. (2021) Treatment advances for pediatric and adult onset neoplasms with monocytosis. Current Hematologic Malignancy Reports 16:3, pages 256-266.
Crossref
Simon Schreiber, Christoph M. Hammers, Achim J. Kaasch, Burkhart Schraven, Anne Dudeck & Sascha Kahlfuss. (2021) Metabolic Interdependency of Th2 Cell-Mediated Type 2 Immunity and the Tumor Microenvironment. Frontiers in Immunology 12.
Crossref
Iwona Kwiatkowska, Justyna Magdalena Hermanowicz, Alicja Przybyszewska-Podstawka & Dariusz Pawlak. (2021) Not Only Immune Escape—The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis. Cancers 13:11, pages 2667.
Crossref
Juyoung Jung, Hongchul Yoon, Te-ik Sohn, Kyusic Jang, Yeongran Yoo, Ilji Jeong, Jae Eui Shin, Jin Hee Lee, Jihyae Ann & Jeewoo Lee. (2021) Discovery of 5-(N-hydroxycarbamimidoyl) benzofuran derivatives as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Bioorganic & Medicinal Chemistry Letters 40, pages 127963.
Crossref
Huizhen Ge, Longfei Mao, Jie Zhao, Yuwei Wang, Danfeng Shi, Xing Yang, Xiaorui Wang, Huanxiang Liu & Xiaojun Yao. (2021) Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays. Journal of Computer-Aided Molecular Design 35:5, pages 679-694.
Crossref
Erez N. Baruch, Jingjing Wang & Jennifer A. Wargo. (2021) Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect. Cancer Immunology Research 9:4, pages 365-370.
Crossref
François-Xavier Danlos, Claudia Grajeda-Iglesias, Sylvère Durand, Allan Sauvat, Mathilde Roumier, Delphine Cantin, Emeline Colomba, Julien Rohmer, Fanny Pommeret, Giulia Baciarello, Christophe Willekens, Marc Vasse, Frank Griscelli, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, Agathe Dubuisson, Lisa Derosa, Nitharsshini Nirmalathasan, Delphine Bredel, Séverine Mouraud, Caroline Pradon, Annabelle Stoclin, Flore Rozenberg, Jérôme Duchemin, Georges Jourdi, Syrine Ellouze, Françoise Levavasseur, Laurence Albigès, Jean-Charles Soria, Fabrice Barlesi, Eric Solary, Fabrice André, Frédéric Pène, Félix Ackerman, Luc Mouthon, Laurence Zitvogel, Aurélien Marabelle, Jean-Marie Michot, Michaela Fontenay & Guido Kroemer. (2021) Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death & Disease 12:3.
Crossref
Yasser Tabana, Isobel S. Okoye, Arno Siraki, Shokrollah Elahi & Khaled H. Barakat. (2021) Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis. Frontiers in Oncology 11.
Crossref
Anjali Rohatgi & John M. Kirkwood. (2021) Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma. Frontiers in Oncology 11.
Crossref
Xin Peng, Youe He, Jun Huang, Yongguang Tao & Shuang Liu. (2021) Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy. Frontiers in Immunology 12.
Crossref
George Anderson, Annalucia Carbone & Gianluigi Mazzoccoli. (2021) Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute Respiratory Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology. International Journal of Molecular Sciences 22:4, pages 1597.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.